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Abstract
Brain tumors are the most common form of solid tumors in children. Due to the increasing number of survivors, it is of
importance to prevent long-term treatment-induced side effects. Montelukast, a leukotriene receptor antagonist, may
have the desired neuroprotective properties. The aim of the study was to determine whether montelukast could
reduce adverse effects of cranial irradiation (CIR) to the young brain. Daily injections of montelukast or vehicle was
given to young mice for 4 or 14 days in combination with CIR or under normal conditions. Montelukast treatment for
4 days protected against cell death with 90% more cell death in the vehicle group compared to the montelukast
group 24 h after CIR. It also resulted in less microglia activation 6 h after CIR, where montelukast lowered the levels of
CD68 compared to the vehicle groups. Interestingly, the animals that received montelukast for 14 days had 50% less
proliferating cells in the hippocampus irrespective of receiving CIR or not. Further, the total number of neurons in the
granule cell layer was altered during the sub-acute phase. The number of neurons was decreased by montelukast
treatment in control animals (15%), but the opposite was seen after CIR, where montelukast treatment increased the
number of neurons (15%). The results show beneﬁcial effects by montelukast treatment after CIR in some investigated
parameters during both the acute phase and with longer drug treatment. However, it also resulted in lower
proliferation in the hippocampus under normal conditions, indicating that the effects of montelukast can be either
beneﬁcial or unfavorable, depending on the circumstances.
Introduction
Children with asthma receive daily treatment and
according to international guidelines the ﬁrst choice
of treatment is inhaled corticosteroids. The treatment
is often combined with adrenergic β2 receptor agonists.
The second choice for treatment is leukotriene receptor
antagonists, for example, montelukast (Singulair®),
which is approved for use in children (<12 years)1. It
is not unusual that the ﬁrst and second choices
are combined. Montelukast has been considered well
tolerated in children due to mild and transient side
effects2. However, current reports show that montelukast
treatment can cause psychiatric adverse drug reactions in
children, such as sleep disorder, anxiety, aggressiveness,
and hyperactivity with an incidence higher than 10%3–5.
The underlying reasons for these side effects remain
unknown.
Leukotrienes are normally present at low levels in the
brain but increase during pathological conditions6.
Montelukast has been described to be neuroprotective,
for example, in the aging brain and after focal cerebral
ischemia7,8. In the aging brain, increased activation of
microglia is accompanied with decreased hippocampal
neurogenesis and cognitive decline7. Daily, oral
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administration of montelukast to rats for 6 weeks
improved these negative changes in the aging brain7,
effects that could also be beneﬁcial in radiotherapy-
induced injury in children.
Brain tumors are the most common form of solid
tumors in children9, with surgery, chemotherapy, and
radiotherapy as the main treatment strategies10. All of
these treatments cause late side effects, with radiotherapy
having the highest severity when graded11. Side effects
range from sleep disturbance to cognitive impairment12.
The mechanisms of chronic radiation-induced damage
involve, for example, long-term toxicity to neural cell
types, including stem and progenitor cells, loss of oligo-
dendrocytes, and inﬂammatory responses13. Cranial
radiotherapy also changes the chemical milieu and affects
supporting cells such as microglia14,15. The subgranular
zone (SGZ) in the hippocampus, an area in the brain that
harbor stem cells, is very sensitive to radiotherapy in both
the young and adult brain, and loss of these cells may
contribute to cognitive deﬁcits16–18. Finding means to
ameliorate radiation-induced injury is of great interest for
the increasing number of long-term childhood cancer
survivors.
Targeting the irradiation-induced inﬂammatory response
is of interest to prevent negative effects on cognition
and neurogenesis. Inhibiting microglia with MW-151, a
selective inhibitor of proinﬂammatory microglial cytokine
production, restored hippocampal-dependent learning,
improved synaptic function, and partially protected neuro-
genesis after cranial irradiation (CIR) to the adult rat
brain19. Further, it has been shown that indomethacin,
a common nonsteroidal anti-inﬂammatory drug, has
the potential to partly increase neurogenesis after CIR
in adults20. Blocking chemokine (C–C motif) receptor 2
(Ccr2) has also prevented neuronal dysfunction and
hippocampal-dependent memory dysfunction induced
by irradiation toward the adult mouse brain21. We have
previously shown that the juvenile and adult brain have
different radiation-induced inﬂammatory responses22,
which is of importance if using an anti-inﬂammatory
approach to protect the brain from CIR-induced injury. In
the developing brain, it has been shown that blocking the
complement cascade can improve reversal learning after
CIR, but without effects on neurogenesis23. As mentioned
earlier, montelukast is a leukotriene receptor antagonist.
Leukotrienes are lipid mediators of inﬂammation and
are metabolized from arachidonic acid through the
5-lipoxygenase (5-LOX) pathway. It has been shown
that minocycline, a tetracycline antibiotic that blocks
the activation of 5-LOX, had positive effects on cognitive
impairment and decreased apoptosis in newborn neurons
(DCX+) following a single dose of 20Gy irradiation to the
brain of 1 month old rats24. Inhibiting the 5-LOX pathway
to target the inﬂammatory response could therefore be an
interesting strategy to investigate when trying to protect the
normal tissue during radiotherapy. The purpose of this
study was to investigate the effect of montelukast in com-
bination with CIR to the young brain.
Results
The study outline is presented in Fig. 1a. Weight gain
was carefully monitored for all mice injected daily for
14 days and an interaction between treatment, drug, and
time was observed (P= 0.036, Fig. 1b–c). CIR resulted in
a signiﬁcantly delayed weight gain compared to control
animals and stayed below the other groups throughout
the experiment. Interestingly, the montelukast group did
not show the same delayed weight gain following CIR.
Acute phase following CIR
To investigate the acute CIR-induced injury, caspase
activity in brain homogenate and neuroﬁlament light
chain (NFL) in serum was measured. Cell death (caspase-
3/7-activity) increased to similar levels in both the vehicle
and the montelukast group at 6 h after CIR (P= 0.0004,
Fig. 2a). The relative increase after CIR was 125% in the
vehicle groups (post hoc, P= 0.0121) and 141% in the
montelukast groups (post hoc, P= 0.0116). Interestingly,
the levels of caspase activity had decreased back to
normal levels at 24 h after CIR. However, there was a
drug effect at this time (P= 0.0078, Fig. 2a) with 90%
more cell death in the CIR vehicle group compared to
the CIR montelukast group (post hoc, P= 0.0357). The
level of NFL, reﬂecting neuronal injury, increased in
serum 6 h after CIR (P= 0.0055, Fig. 2b). This trend was
seen in both the vehicle (post hoc, 58%, P= 0.1136) and
the montelukast groups (post hoc, 77%, P= 0.0565).
However, no difference was observed between the dif-
ferent groups at 24 h after CIR.
Cluster of differentiation 68 (CD68) and chemokine
(C–C motif) ligand 2 (CCL2) were measured in brain
homogenate to evaluate the inﬂammatory response fol-
lowing CIR. The level of CD68 was signiﬁcantly altered
6 h after CIR (P= 0.0128, Fig. 2c). At this time point
montelukast lowered the levels of CD68 compared to
both vehicle groups (post hoc, n.s.). The levels of CCL2
increased signiﬁcantly after CIR in both vehicle and
montelukast groups at both time points (P < 0.0001,
Fig. 2d). The vehicle group showed a CIR-induced
increase of 298% (post hoc, P < 0.0001) and the mon-
telukast group a CIR-induced increase of 254% (post
hoc, P < 0.0001) 6 h after the injury.
Sub-acute phase following CIR
Twelve days after CIR, the volumes of corpus callosum,
thalamus, and dentate gyrus were measured (Fig. 3a–b).
The volume of corpus callosum was smaller following CIR
for both vehicle and montelukast groups (P= 0.0115,
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Fig. 3c). For vehicle animals, it was 25% smaller (post hoc,
P= 0.0334) and for the montelukast group the decrease
was 13.4% (post hoc, n.s). No difference was observed in
the thalamic region or the dentate gyrus (Fig. 3d–e).
However, an analysis of the subregions in the dentate
gyrus revealed that the volumes of the granule cell layer
(GCL, P= 0.0228, Fig. 3f) and hilus (P= 0.0243, Fig. 3h)
changed following CIR. The CIR vehicle group had a
smaller volume compared to the control vehicle group
in the GCL (9.8%, post hoc, n.s.) and the hilus (16.6%, post
hoc, n.s.). The CIR montelukast group also had a smaller
volume compared to the non-irradiated montelukast
group in the GCL (17.4%, post hoc, n.s., P= 0.0827) and
the hilus (16.0%, post hoc, n.s.). There was no difference
in the molecular layer (ML) (Fig. 3h).
Cellular effects in the GCL were assessed by deter-
mining the total numbers of neurons (NeurotraceTM),
proliferating cells (Ki-67+) and newborn neurons (dou-
blecortin, DCX+). Analysis of the total number of neurons
revealed a signiﬁcant interaction between treatment and
drug (P= 0.0364, Fig. 4a–b). The vehicle CIR group had
23% less neurons in the GCL compared to vehicle con-
trols. This was not observed in the montelukast group,
where CIR did not alter the levels of neurons. Interest-
ingly, montelukast treatment decreased the number
of neurons with 15% when comparing vehicle controls
and montelukast controls. Proliferation was assessed
by quantifying the number of Ki-67+ cells (Fig. 4c–d).
Montelukast decreased proliferation during normal
conditions with 50% (post hoc, P= 0.0291), while CIR
did not signiﬁcantly alter the proliferation levels.
The total number of newborn neurons (DCX+) was
decreased in the GCL after CIR but not altered by mon-
telukast (P < 0.0001, Fig. 4e–f). CIR treatment decreased
the level of newborn neurons with 63% in the vehicle
CIR group compared to vehicle controls (post hoc,
P < 0.0001) and 55% in the montelukast CIR group com-
pared to montelukast controls (post hoc, P < 0.0001).
To investigate effects on non-neuronal cells in the
dentate gyrus, microglia (Iba+), oligodendrocytes
(Olig2+), and astrocytes (S100+, possibly including a
subpopulation of neurons) were quantiﬁed. The number
of microglia was affected by both montelukast treatment
(P= 0.0233) and CIR (P= 0.015, Fig. 5a–b). However,
the post hoc test only revealed a difference between the
vehicle control group and the montelukast CIR group in
GCL (post hoc, P= 0.0066). Similar trends were observed
in the hilus and ML. Further, the number of oligoden-
drocytes decreased following CIR in GCL (P < 0.0001),
hilus (P= 0.00005), and ML (P= 0.000243, Fig. 5c–d). No
effect was observed following montelukast treatment.
In the GCL, the vehicle CIR group had 23% less
Fig. 1 Study outline and weight gain. a Study outline. The weight was measured daily throughout the experiment. The entire period is shown in
(b). A lag in weight gain was observed in the groups that received CIR (1). The montelukast groups weaned 1 day later than the vehicle groups (2).
The days before and after CIR are zoomed in (c). CIR cranial irradiation, IHC immunohistochemistry. †= sacriﬁce. ncontrol vehicle= 10, ncontrol montelukast
= 9, nCIR vehicle= 6, nCIR montelukast= 7. Statistical results from three-way ANOVA are presented in the ﬁgures, *= interaction between treatment, drug,
and time. *P= 0.036
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oligodendrocytes compared to the vehicle controls (post
hoc, P= 0.039). For the montelukast CIR group, the
relative reduction of oligodendrocytes in the GCL was
38% compared to the montelukast control group (post
hoc, P= 0.0007). Similar changes were observed in the
hilus and the ML for both vehicle and montelukast
groups. The number of S100+ cells was not affected by
montelukast or CIR treatment (Fig. 5e–f).
Discussion
Radiotherapy is an effective treatment for brain tumors
but unfortunately causes long-lasting side effects in the
brain. In this study, parameters that are known to be
affected by CIR were investigated to evaluate the effect
of montelukast on radiation-induced injury in the devel-
oping brain. The major ﬁndings were the following:
(1) Montelukast treatment resulted in reduced cell death
during the acute phase after CIR. (2) The number of
neurons was altered by montelukast treatment with a
positive effect after CIR, but with a negative effect during
normal conditions. (3) Proliferation in the hippocampal
neurogenic zone decreased by montelukast treatment.
These data indicate that the effects of montelukast can
be either beneﬁcial or unfavorable, depending on the
physiological conditions.
Delayed weight gain has previously been observed
after CIR to the developing brain25, but the underlying
mechanism is not clear. Two possibilities, which are often
seen in patients, are alterations in the hormonal balance
or injury to the mucous membrane. A CIR-induced injury
in the mucosa in the mouth and throat would make it
painful for the mice to eat. Regarding the hormonal levels,
the thyroid hormones FT3 and FT4 have been shown
to be unaffected 4 months after CIR in a similar mouse
model26. Presumably, the delayed weight gain is an
effect of both hypothalamic–pituitary axis dysfunction
Fig. 2 Markers of neuronal injury and inﬂammation were measured following CIR and montelukast treatment. a Levels of caspase-3/7-
activity, reﬂecting cell death. b NFL in serum, reﬂecting neuronal injury. c Levels of CD68, reﬂecting microglial activation. d Levels of CCL2, reﬂecting
the proinﬂammatory response. CCL2 chemokine (C–C motif) ligand 2, CD68 cluster of differentiation 68, CIR cranial irradiation, NFL neuroﬁlament
light chain. a ncontrol vehicle 6 h= 5, ncontrol montelukast 6 h= 5, nCIR vehicle 6 h= 5, nCIR montelukast 6 h= 5, ncontrol vehicle 24 h= 5, ncontrol montelukast 24 h= 4,
nCIR vehicle 24 h= 5, nCIR montelukast 24 h= 5. b ncontrol vehicle 6 h= 9, ncontrol montelukast 6 h= 9, nCIR vehicle 6 h= 5, nCIR montelukast 6 h= 6,
ncontrol vehicle 24 h= 7, ncontrol montelukast 24 h= 7, nCIR vehicle 24 h= 5, nCIR montelukast 24 h= 5. c, d n= 5 for all groups. Error bars indicate ± SEM.
Statistical results from two-way ANOVA are presented in the ﬁgures. ¤= treatment (control/CIR), #= drug (vehicle/montelukast), #P < 0.05, ¤¤P < 0.01,
¤¤¤P < 0.001, ¤¤¤¤P < 0.0001
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and injury in the mucous membrane. Here, CIR caused a
signiﬁcantly delayed weight gain in the vehicle group but
not in the montelukast group. The different reactions
after CIR suggest that montelukast may have a protective
effect on the physiological response to CIR, possibly due
to its anti-inﬂammatory effects.
Acute cell death and increased levels of the neuronal
injury marker, NFL, in serum are two expected ﬁndings
following CIR, especially in a still developing brain27,28.
In this study, the vehicle group exhibited more cell death
compared to the montelukast group acutely following
CIR. It has been demonstrated that montelukast could
increase the proliferation of neuronal precursor cells
in vitro through the receptors CysLT1R and GPR1729.
However, there was no effect on cell fate or differentiation
in that study. In this in vivo study, we observed the
opposite. Montelukast rather had a negative effect on
both proliferation and maturation under control condi-
tions. It is possible that montelukast administration
immediately negatively affected the cell proliferation,
resulting in less proliferating cells at the time of CIR. This
would then be reﬂected by less cell death. Further, it
has been shown that microglia express, for example,
GPR1730,31, and it is therefore possible that montelukast
have a direct impact on microglia which would affect both
the levels of CD68 and Iba1. Also, microglia themselves
could affect the injury since they are known producers
of reactive oxygen species and proinﬂammatory factors32,
and excess of these factors can worsen brain injury.
Interestingly, montelukast had a positive effect on the
Fig. 3 Volumetric alterations following CIR and montelukast treatment. a Investigated areas are highlighted in the schematic overview.
The hippocampal regions are illustrated in b. The volumes were measured in the corpus callosum (c), thalamus (d), and hippocampal dentate
gyrus (e). The subregions of the dentate gyrus; GCL (f), hilus (g), and molecular layer (h) are also presented. CC corpus callosum, CIR cranial
irradiation, DG dentate gyrus, GCL granule cell layer, ML molecular layer, Th thalamus. c ncontrol vehicle= 7, ncontrol montelukast= 9, nCIR vehicle= 6,
nCIR montelukast= 5. d ncontrol vehicle= 9, ncontrol montelukast= 9, nCIR vehicle= 6, nCIR montelukast= 7, e, f, g, h ncontrol vehicle= 8, ncontrol montelukast= 9,
nCIR vehicle= 6, nCIR montelukast= 5. Error bars indicate ± SEM. Statistical results from two-way ANOVA are presented in the ﬁgures, ¤= treatment
(control/CIR), ¤P < 0.05
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number of mature neurons after CIR, but not on the
number of proliferating cells or newborn neurons. Hence,
the survival of newborn neurons was positively affected
in this scenario.
Montelukast has been tested in neurological conditions
where inﬂammation and cognitive dysfunction is of
interest. For example, montelukast acutely protects cere-
bral tissue in neonatal rats following ischemic brain
damage33. These ﬁndings are in line with our results with
lower levels of cell death in the montelukast group fol-
lowing CIR. Another study has shown beneﬁcial effects
on spatial memory and cognition in the aging brain
after montelukast treatment7. An in vitro study showed
an increased proliferation of neuronal progenitors
after montelukast administration, but using higher doses
it decreased proliferation29. This support our ﬁnding
that montelukast could have a negative effect on neuronal
proliferation in the intact juvenile brain.
Whether montelukast is beneﬁcial or not seems to
depend on the absence or presence of injury in the
young brain. Positive results from montelukast treatment
have been seen in the aging brains of rats after a dose
of 10 mg/kg body weight7. The dose to treat asthma in
children (2–5 years old) is however 4 mg/day regardless
of body weight. In this study, we have examined the
effects of montelukast in the young brain after CIR at
Fig. 4 Cellular effects in the GCL following CIR and montelukast treatment. a A microphotograph of NeurotraceTM in the dentate gyrus.
b Neurons were quantiﬁed in the GCL where a signiﬁcant interaction was observed. c Proliferating cells, assessed by Ki-67+ staining. d Ki-67+
quantiﬁcation in the hippocampal neurogenic SGZ. e Newborn cells, measured as total numbers of DCX+ cells. f DCX+ quantiﬁcation in the SGZ.
a Scale bar 20 µm. b ncontrol vehicle= 8, ncontrol montelukast= 9, nCIR vehicle= 6, nCIR montelukast= 6. c Scale bar 50 µm. d ncontrol vehicle= 9, ncontrol montelukast
= 8, nCIR vehicle= 5, nCIR montelukast= 4. e Scale bar 50 µm. f ncontrol vehicle= 8, ncontrol montelukast= 9, nCIR vehicle= 6, nCIR montelukast= 5. CIR cranial
irradiation, DCX doublecortin, GCL granule cell layer, SGZ subgranular zone. Error bars indicate ± SEM. Statistical results from two-way ANOVA
are presented in the ﬁgures, ¤= treatment (control/CIR), #= drug (vehicle/montelukast), *= interaction between treatment and drug. *P < 0.05,
#P < 0.05, ¤¤¤¤P < 0.0001
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the same dose as in the aging study, 10 mg/kg, but during
a shorter time course compared to the clinical situation.
Our aim was to investigate if this dose of montelukast
could have similar protective effects after CIR, as the
damage resembles the aging brain with elevated inﬂam-
mation and less proliferation. Nevertheless, our ﬁndings
could also contribute to explaining some alterations
that montelukast induce in the young healthy brain as
we have seen negative effects both acutely and after
2 weeks of daily administration of montelukast. However,
more studies are needed to explore the therapeutic win-
dow for montelukast in pediatric patients. It should be
emphasized that asthma itself can induce hypoxia in the
brain, leading to, for example, cognitive dysfunction34.
A future perspective could be to investigate if montelukast
is a good treatment in such cases to control asthma and
Fig. 5 Effects on non-neuronal cells in the dentate gyrus following CIR and montelukast treatment. A microphotograph (a) and
quantiﬁcations (b) of microglia (Iba1+) in subregions of the dentate gyrus (GCL, hilus, and ML). A microphotograph (c) of oligodendrocytes (Olig2+),
and subsequent quantiﬁcations in subregions of the dentate gyrus (d). A microphotograph (e) and quantiﬁcations (f) of astrocytes (S100+) in
subregions of the dentate gyrus. CIR cranial irradiation, GCL granule cell layer, Iba1 ionized calcium-binding adapter molecule 1, ML molecular layer,
Olig2 oligodendrocyte transcription factor 2, S100 S100 calcium-binding protein. a, c, e Scale bar= 50 µm. b ncontrol vehicle= 8, ncontrol montelukast= 9,
nCIR vehicle= 6, nCIR montelukast= 5. d ncontrol vehicle= 7, ncontrol montelukast= 8, nCIR vehicle= 6, nCIR montelukast= 5. f ncontrol vehicle= 10,
ncontrol montelukast= 9, nCIR vehicle= 6, nCIR montelukast= 7. Statistical results from two-way ANOVA are presented in the ﬁgures, ¤= treatment
(control/CIR), #= drug (vehicle/montelukast), ¤#P < 0.05, ¤¤¤P < 0.001, ¤¤¤¤P < 0.0001
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at the same time minimize injuries from the hypoxia for
this group of children.
In summary, montelukast has negative effects on the
maturation of the GCL during normal conditions,
whereas during a pathological condition, such as follow-
ing CIR, the effects can be protective. These ﬁndings,
with the affected proliferation during normal conditions,
in combination with the new proﬁle for psychiatric
adverse drug reactions, suggests that prescribing mon-
telukast to young children should be a well thought
through decision. However, more studies are needed to
investigate if the negative effects are occurring also at




C57BL/6J mice with six female pups per mother were
ordered from Charles River Laboratories, Germany.
Animals were housed according to normal procedures at
the Experimental Biomedicine animal facility (University
of Gothenburg, Gothenburg, Sweden). The mice were
kept on a 12-h light cycle with food and water provided
ad libitum. The room temperature was 19–21 °C with
40–70% relative humidity. Animal experiments were
approved by the Gothenburg committee of the Swedish
Animal Welfare Agency (2015–72).
Montelukast treatment
Montelukast sodium powder (Sigma, USA) was dis-
solved in 99.5% ethanol, diluted 1:10 with 0.9% saline
(NaCl), and administered by intraperitoneal injections
at a dose of 10 mg/kg. Animals (n= 6–10) received daily
injections of montelukast or vehicle (0.9% NaCl with 10%
ethanol) starting 2 days before CIR, resulting in four
doses for the acute study and 14 doses for the sub-acute
study (Fig. 1a).
Cranial irradiation procedure
A linear accelerator True Beam STX (600 MU/min, 5.6
Gy/min; Radiation Oncology Systems, USA) with 6 MV
nominal photon energy was used for CIR as described
earlier28. Brieﬂy, all animals were anesthetized on post-
natal day 21 with a mixture of oxygen and isoﬂurane
(Attane Vet, VM Pharma AB, Sweden) to immobilize the
animals during the procedure. The whole brain was
irradiated with a clinically relevant dose of 2 × 4 Gy with
12-h interval, using a radiation ﬁeld of 2 × 2 cm, a source
to skin distance of 99.5 cm, and a dose variation of ±5%.
After CIR, animals were returned to their dams. Control
animals were anesthetized but did not receive CIR.
Typically, pediatric patients with brain tumors are treated
with radiotherapy, once a day, 5 days per week, for several
weeks. The treatment protocol varies depending on tumor
type and other relevant factors, but often it is 50–59.4 Gy
in 28–33 fractions of 1.8 Gy. This study was designed to
investigate the radiation-induced injury in the normal
tissue (8 Gy given in two fractions), hence a much lower
dose than the tumor bed receive.
Acute tissue preparation
Brains were quickly removed after sacriﬁce, put in
liquid nitrogen and stored at −80 °C. Brains were
homogenized by sonication in phosphate-buffered saline
containing Triton X-100 (Merck KGaA, Germany),
ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich,
USA), and protease inhibitor cocktail (cOmplete, EDTA-
free, Roche, Switzerland). Samples were then centrifuged
and supernatant stored at −80 °C. Protein concentration
was measured using the Pierce BCA protein Assay Kit
(Thermo Scientiﬁc, USA) according to the protocol pro-
vided by the manufacturer.
Sub-acute tissue preparation
Animals were anesthetized with sodium pentobarbital
(Pentothal, Electra-box Pharma, Sweden) and transcar-
dially perfused with 0.1M phosphate buffer (pH 7.5) to
rinse the vascular system, followed by 6% formaldehyde
(pH 7.4; Histoﬁx; Histolab Products AB, Sweden). Brains
were gently removed, immersion-ﬁxed in Histoﬁx for
24 h and stored in a sucrose solution (30% sucrose in
0.1M phosphate buffer, pH 7.5). The right hemisphere
was cut sagittally into 25 µm sections in a series of
12, using a sliding microtome (SM2010R, Leica Micro-
systems, Germany), and stored at 4 °C in a cryoprotectant
solution (25% ethylene glycol and 25% glycerol).
Blood collection
Mice were anesthetized with a mixture of oxygen and
isoﬂurane, blood was drawn from the heart with a 1 mL
syringe (Omniﬁx®, BRAUN, Germany) and centrifuged
for 5 min. Serum was collected and stored at −80 °C.
Fluorometric assay of caspase-3-like activity
Caspase-dependent cell death was measured using a
caspase activity assay. An aliquot of 20 µl tissue homo-
genate was added to a microplate and mixed with 80 µl
extraction buffer (n= 5, duplicate samples) and analyzed
as described earlier35. Cleavage of Ac-DEVD-AMC
(for caspase-3/7-activity, Peptide Institute, Japan, cat.
no.3171-v) was measured and expressed as pmol AMC
released per mg protein and minute.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assays (ELISA) were
used to investigate chemokine (C–C motif) ligand 2
(CCL2, MJE00, R&D Systems, USA) and cluster of dif-
ferentiation 68 (mouse CD68, EKM1518, Nordic BioSite,
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Sweden) expression. Analyses were performed according
to instructions of the manufacturers and the amount of
investigated proteins measured using a SpectraMax i3x
(Molecular Devices, USA).
Serum NFL
Serum sample neuroﬁlament light chain (NFL) con-
centration was determined using an in-house NFL assay
on the single molecule array (Simoa) platform, which has
been described in detail previously36. Brieﬂy, para-
magnetic carboxylated beads (Quanterix Corp, USA) were
coated with a mouse anti-NFL antibody (UD1, Uman-
Diagnostics, Sweden) and incubated with sample and a
biotinylated mouse anti-NFL antibody (UD2, Uman-
Diagnostics, Sweden) in a Simoa HD-1 instrument
(Quanterix).
Immunohistochemistry
Sections were treated as follows: rinsed (always in Tris-
buffered saline [TBS], 50 mM Tris-HCl in 150mM NaCl),
incubated in 0.6% H2O2 in TBS for 30min, rinsed and
incubated for 30min in a TBS block solution with 3%
donkey serum (Jackson ImmunoResearch Laboratories
Inc, USA), and 0.1% Triton X-100 (Merck KGaA, Ger-
many). Sections were incubated overnight at 4 °C in block
solution using the following primary antibodies: oligo-
dendrocyte transcription factor 2 (1:500, rabbit anti-Olig2,
ab109186, Abcam, UK), marker of proliferation Ki-67
(1:1000, rabbit anti-Ki-67, ab15580, Abcam, UK), S100
calcium-binding protein (1:2000, mouse anti-S100, MA5-
12969, ThermoFisher Scientiﬁc, USA), rabbit anti-ionized
calcium-binding adapter molecule 1 (1:1000, rabbit anti-
Iba1, 019-19741, WAKO Pure Chemical Industries ltd,
Japan), and doublecortin (1:500, polyclonal goat anti-
DCX, Santa Cruz Biotechnology, USA). Sections were
rinsed, incubated for 1 h with block solution and bioti-
nylated secondary antibodies (1:1000, Jackson Immu-
noResearch Laboratories Inc, USA), rinsed and incubated
with avidin-biotin-peroxidase (10 µL/mL TBS of A and B,
Vectastain Elite ABC Kit, Vector Laboratories, USA) for
1 h. Sections were rinsed and developed in 3,3′-diamino-
benzidine (DAB, Saveen Werner AB, Sweden) diluted in
TBS with H2O2 and NiCl2, until sufﬁcient color was
noted. After rinsing in tap water, sections were mounted
using 0.1M phosphate buffer, pH 7.5, and dried over-
night, then cover slipped with X-Tra-Kitt (Medite GmbH,
Germany).
NeuroTrace Fluorescent Nissl stain
Sections were rinsed in TBS and then washed in TBS
with 0.1% Triton X-100 for 10min. After further washing,
sections were incubated with NeuroTraceTM 500/525
Green Fluorescent Nissl stain for 20 min (N21480,
ThermoFisher Scientiﬁc, USA). Following several rinsing
steps in TBS, the sections were mounted and cover slip-
ped with ProLong® Gold Antifade Reagent (Thermo-
Fisher Scientiﬁc, USA).
Stereological procedures
Cells were counted in every 12th section using
systematic-random sampling (Stereoinvestigator, Micro-
BrightField, USA) and a Leica DM6000 B microscope
(Leica Microsystems, Germany). Counting started
on sections containing a clearly divided dorsal and
ventral hippocampus (only the dorsal granule cell layer
[GCL] was measured). Total volumes were calculated
according to the Cavalieri principle (V= SA × P × T,
where V is the total volume, SA is the sum of area mea-
surements, P is the inverse of the sampling fraction, and T
is the section thickness). The total number of cells was
obtained by dividing the number of counted cells with the
sampling fraction. Volumes for corpus callosum and
thalamus were also measured in sections eligible for
hippocampal quantiﬁcations.
NeuroTrace was used to quantify neurons in GCL (×40
objective). A 275 × 75-µm grid was randomly placed over
the traced area and counting frames (25 × 25 µm) were
placed within the grid. The total number of GCL neurons
per animal was calculated by dividing the number of
counted cells with the sampling fractions, i.e., fraction of
sampling area/total traced area × series fraction (1/12) ×
optical dissector height/physical section thickness.
Statistics
For statistical analyses, two-way ANOVA was used
(drug and treatment as main effects), followed by a post
hoc test (Sidak, corrected for multiple testing using
GraphPad Prism 7.02). Weight was analyzed using three-
way ANOVA (Stata). Statistical signiﬁcance was con-
sidered if P < 0.05.
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